Advertisement

Human Cell

, Volume 32, Issue 1, pp 64–74 | Cite as

Microvesicles derived from human bone marrow mesenchymal stem cells promote U2OS cell growth under hypoxia: the role of PI3K/AKT and HIF-1α

  • Shanshan Lin
  • Bo Zhu
  • Guozhi Huang
  • Qing Zeng
  • Chuhuai WangEmail author
Research Article

Abstract

Studies have demonstrated that mesenchymal stem cells (MSCs) can promote tumor growth, and MSC microvesicles (MVs) are very important in the tumor microenvironment and information transfer between cells during tumorigenesis and development. However, the potential effects and mechanisms of MSC-MVs on tumor growth are still controversial. Here in this study, we investigated the roles and effects of human bone marrow MSC-MVs (hBMSC-MVs) on human osteosarcoma (U2OS) cell growth under hypoxia in vitro and in vivo. BMSC-MVs were harvested and purified by ultracentrifugation. U2OS cells were treated with different concentrations of hBMSC-MVs under hypoxia. Cell viability and migration was measured by MTT test, transwell invasion assay and scratch migration assay. The expression of the signaling molecules of AKT, VEGF, GLUT1 and Bax, cleaved-caspase3 in U2OS cells cultured with MVs under hypoxia was determined by western blot. U2OS/siHIF-1α or U2OS/NC cells mixed with/without MVs were subcutaneously injected into nude mice; the tumor size and weight were detected. We found that hBMSC-MVs promoted U2OS cell proliferation and migration under hypoxia in vitro, and that was partially associated with the PI3K/AKT and HIF-1α pathways. MVs co-injected with U2OS cells promoted tumor growth in a mouse xenograft model. siHIF-1α transfection reversed these changes to some extent. The function of hBMSC-MVs on U2OS cell progression and tumor growth was associated with PI3K/AKT and HIF-1α pathway under hypoxia. These findings support a new mechanism suggesting the contribution of MSC-MVs to tumor growth.

Keywords

Microvesicles Osteosarcoma Hypoxia PI3K/AKT HIF-1α 

Notes

Acknowledgements

The authors thank professor Guo for his technical support and critical discussions.

Compliance with ethical standards

Ethical approval

All experimental procedures were approved by the Medical Ethical Committee of the Sun Yat-sen University and the Ethical Commission Academy of Military Medicine Science, both of which approved the use of mice for this study (D11-2050 and D11-1004) [SCXK(Jing) 2012-0001]. All applicable international, national, and institutional guidelines for the care and use of animals were followed.

Research involving human and/or animal participants

All procedures performed in studies involving human participants were in accordance with the ethical standards of the Institutional Medical Research Ethics Committee of the First Affiliated Hospital of Sun Yat-sen University, and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Conflict of interest

All the authors confirm that no financial or non-financial conflict of interests exists.

References

  1. 1.
    Jo VY, Doyle LA. Refinements in sarcoma classification in the current 2013 World Health Organization classification of tumours of soft tissue and bone. Surg Oncol Clin N Am. 2016;25;621–43.CrossRefGoogle Scholar
  2. 2.
    Nieto-Coronel MT, López-Vásquez AD, Marroquín-Flores D, Ruiz-Cruz S, Martínez-Tláhuel JL, De la Garza-Salazar J. Central nervous system metastasis from osteosarcoma: case report and literature review. Rep Pract Oncol Radiother. 2018;23:266–9.CrossRefGoogle Scholar
  3. 3.
    Knowles HJ, Schaefer K, Dirksen U, Athanasou NA. Hypoxia and hypoglycaemia in Ewing’s sarcoma and osteosarcoma: regulation and phenotypic effects of hypoxia-inducible factor. BMC Cancer. 2010;10:372.CrossRefGoogle Scholar
  4. 4.
    Rohwer N, Cramer T. Hypoxia-mediated drug resistance: Novel insights on the functional interaction of HIFs and cell death pathways. Drug Resist Updates. 2011;14:191–201.CrossRefGoogle Scholar
  5. 5.
    Semenza GL. Molecular mechanisms mediating metastasis of hypoxic breast cancer cells. Trends Mol Med. 2012;18:534–43.CrossRefGoogle Scholar
  6. 6.
    Burkitt K, Chun SY, Dang DT, Dang LH. Targeting both HIF-1 and HIF-2 in human colon cancer cells improves tumor response to sunitinib treatment. Mol Cancer Ther. 2012;8:1148–56.CrossRefGoogle Scholar
  7. 7.
    Zhou B, Si W, Su Z, Deng W, Tu X, Wang Q. Transcriptional activation of the Prox1 gene by HIF-1α and HIF-2α in response to hypoxia. FEBS Lett. 2013;587:724–31.CrossRefGoogle Scholar
  8. 8.
    Samanta D, Semenza GL. Metabolic adaptation of cancer and immune cells mediated by hypoxia-inducible factors. Biochim Biophys Acta Rev Cancer. 2018;1870(1):15–22.CrossRefGoogle Scholar
  9. 9.
    Schito L. Bridging angiogenesis and immune evasion in the hypoxic tumor microenvironment. Am J Physiol Regul Integr Comp Physiol. 2018.  https://doi.org/10.1152/ajpregu.00209.2018.Google Scholar
  10. 10.
    de Gortázar AR, Alonso V, Alvarez-Arroyo MV, Esbrit P. Transient exposure to PTHrP (107–139) exerts anabolic effects through vascular endothelial growth factor receptor 2 in human osteoblastic cells in vitro. Calcif Tissue Int. 2006;79:360–9.CrossRefGoogle Scholar
  11. 11.
    Park H, Min K, Kim H, Jung WW, Park Y. Expression of vascular endothelial growth factor-C and its receptor in osteosarcomas. Pathol Res Pract. 2008;204:575–82.CrossRefGoogle Scholar
  12. 12.
    Kondo K, Klco J, Nakamura E, Lechpammer M, Kaelin WG Jr. Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell. 2002;1:237–46.CrossRefGoogle Scholar
  13. 13.
    Le Goff X, Chesnel F, Delalande O, et al. Aggregation dynamics and identification of aggregation-prone mutants of the von Hippel-Lindau tumor suppressor protein. J Cell Sci. 2016;129:2638–50.CrossRefGoogle Scholar
  14. 14.
    Kim JA, Choi DK, Min JS, et al. VBP1 represses cancer metastasis by enhancing HIF-1α degradation induced by pVHL. FEBS J. 2018;285:115–26.CrossRefGoogle Scholar
  15. 15.
    Joshi S, Singh AR, Zulcic M, Durden DL. A macrophage-dominant PI3K isoform controls hypoxia-induced HIF1α and HIF2α stability and tumor growth, angiogenesis, and metastasis. Mol Cancer Res. 2014;12:1520–31.CrossRefGoogle Scholar
  16. 16.
    Zhong H, Chiles K, Feldser D, et al. Modulation of hypoxia-inducible factor 1α expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Can Res. 2000;60:1541–45.Google Scholar
  17. 17.
    Nilsson MB, Zage PE, Zeng L, et al. Multiple receptor tyrosine kinases regulate HIF-1alpha and HIF-2alpha in normoxia and hypoxia in neuroblastoma: implications for antiangiogenic mechanisms of multikinase inhibitors. Oncogene. 2010;29:2938–49.CrossRefGoogle Scholar
  18. 18.
    Liu KH, Huynh N, Patel O, Shulkes A, Baldwin G, He H. P21-activated kinase 1 promotes colorectal cancer survival by up-regulation of hypoxia-inducible factor-1α. Cancer Lett. 2013;340:22–9.CrossRefGoogle Scholar
  19. 19.
    Fang J, Xia C, Cao Z, Zheng JZ, Reed E, Jiang BH. Apigenin inhibits VEGF and HIF-1 expression viaPI3K/AKT/p70S6K1 and HDM2/p53 pathways. FASEB J. 2005;19:342–53.CrossRefGoogle Scholar
  20. 20.
    Barry FP, Murphy JM. Mesenchymal stem cells: clinical applications and biological characterization. Int J Biochem Cell Biol. 2004;36:568–84.CrossRefGoogle Scholar
  21. 21.
    Lin SS, Zhu B, Guo ZK, et al. Bone marrow mesenchymal stem cell-derived microvesicles protect rat pheochromocytoma PC12 cells from glutamate-induced injury via a PI3K/Akt dependent pathway. Neurochem Res. 2014;39:922–31.CrossRefGoogle Scholar
  22. 22.
    Boomsma RA, Geenen DL. Mesenchymal stem cells secrete multiple cytokines that promote angiogenesis and have contrasting effects on chemotaxis and apoptosis. PLoS One. 2012;7:e35685.CrossRefGoogle Scholar
  23. 23.
    Djouad F, Bony C, Apparailly F, Louis-Plence P, Jorgensen C, Noël D, et al. Earlier onset of syngenic tumors in the presence of mesenchymal stem cells. Transplantation. 2006;82:1060–6.CrossRefGoogle Scholar
  24. 24.
    Zheng Y, Wang G, Chen R, Hua Y, Cai Z. Mesenchymal stem cells in the osteosarcoma microenvironment: their biological properties, influence on tumor growth, and therapeutic implications. Stem Cell Res Ther. 2018;9:22.CrossRefGoogle Scholar
  25. 25.
    Yu JM, Jun ES, Bae YC, Jung JS. Mesenchymal stem cells derived from human adipose tissues favor tumor cell growth in vivo. Stem Cells Dev. 2008;17:463–73.CrossRefGoogle Scholar
  26. 26.
    Xu S, Menu E, De Becker A, Van Camp B, Vanderkerken K, Van Riet I. Bone marrow-derived mesenchymal stromal cells are attracted by multiple myeloma cell-produced chemokine CCL25 and favor myeloma cell growth in vitro and in vivo. Stem Cells. 2012;30(2):266–79.CrossRefGoogle Scholar
  27. 27.
    Tsai KS, Yang SH, Lei YP, et al. Mesenchymal stem cells promote formation of colorectal tumors in mice. Gastroenterology. 2011;141:1046–56.CrossRefGoogle Scholar
  28. 28.
    Zhu W, Huang L, Li Y, et al. Mesenchymal stem cell-secreted soluble signaling molecules potentiate tumor growth. Cell Cycle. 2011;10:3198–07.CrossRefGoogle Scholar
  29. 29.
    Al-Nedawi K, Meehan B, Micallef J, et al. Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells. Nat Cell Biol. 2008;10:619–24.CrossRefGoogle Scholar
  30. 30.
    Muralidharan-Chari V, Clancy JW, Sedgwick A, D’Souza-Schorey C. Microvesicles: mediators of extracellular communication during cancer progression. J Cell Sci. 2010;123:1603–11.CrossRefGoogle Scholar
  31. 31.
    Qi J, Zhou Y, Jiao Z, et al. Exosomes derived from human bone marrow mesenchymal stem cells promote tumor growth through hedgehog signaling pathway. Cell Physiol Biochem. 2017;42:2242–54.CrossRefGoogle Scholar
  32. 32.
    Zhu W, Huang L, Li Y, et al. Exosomes derived from human bone marrow mesenchymal stem cells promote tumor growth in vivo. Cancer Lett. 2012;315:28–37.CrossRefGoogle Scholar
  33. 33.
    Alhadlaq A, Mao JJ. Mesenchymal stem cells: isolation and therapeutics. Stem Cells Dev. 2004;13:436–48.CrossRefGoogle Scholar
  34. 34.
    Gatti S, Bruno S, Deregibus MC, et al. Microvesicles derived from human adult mesenchymal stem cells protect against ischaemia–reperfusion-induced acute and chronic kidney injury. Nephrol Dial Transpl. 2011;26:1474–83.CrossRefGoogle Scholar
  35. 35.
    Zhang HC, Liu XB, Huang S, et al. Microvesicles derived from human umbilical cord mesenchymal stem cells stimulated by hypoxia promote angiogenesis both in vitro and in vivo. Stem Cells Dev. 2012;21:3289–97.CrossRefGoogle Scholar
  36. 36.
    Collino F, Deregibus MC, Bruno S, et al. Microvesicles derived from adult human bone marrow and tissue specific mesenchymal stem cells shuttle selected pattern of miRNAs. PLoS One. 2010;5:436–48.CrossRefGoogle Scholar
  37. 37.
    Sowter HM, Raval RR, Moore JW, et al. Predominant role of hypoxia-inducible transcription factor (Hif)-1α versus Hif-2α in regulation of the transcriptional response to hypoxia. Can Res. 2003;63:;6130–34.Google Scholar
  38. 38.
    Warnecke C, Zaborowska Z, Kurreck J, et al. Differentiating the functional role of hypoxia-inducible factor (HIF)-2α and HIF-2α (EPAS-1) by the use of RNA interference: erythropoietin is a HIF-2α target gene in Hep3B and Kelly cells. FASEB J. 2004;18:1462–64.CrossRefGoogle Scholar
  39. 39.
    Yamamoto KR, Alberts BM, Benzinger R, et al. Rapid bacteriophage sedimentation in the presence of polyethylene glycol and its application to large-scale virus purification. Virology. 1970;40:1603–11.CrossRefGoogle Scholar
  40. 40.
    Beasley NJ, Leek R, Alam M, et al. Hypoxia-inducible factors HIF-1α and HIF-2α in head and neck cancer: relationship to tumor biology and treatment outcome in surgically resected patients. Can Res. 2002;62:2493–97.Google Scholar
  41. 41.
    Mizobuchi H, García-Castellano JM, Philip S, et al. Hypoxia markers in human osteosarcoma: an exploratory study. Clin Orthop Relat Res. 2008;466:2052–59.CrossRefGoogle Scholar
  42. 42.
    Goudarzi H, Iizasa H, Furuhashi M, et al. Enhancement of in vitro cell motility and invasiveness of human malignant pleural mesothelioma cells through the HIF-1α-MUC1 pathway. Cancer Lett. 2013;339:82–92.CrossRefGoogle Scholar
  43. 43.
    Onishi H, Morisaki T, Nakao F, et al. Protein-bound polysaccharide decreases invasiveness and proliferation in pancreatic cancer by inhibition of hedgehog signaling and HIF-1α pathways under hypoxia. Cancer Lett. 2013;335:289–98.CrossRefGoogle Scholar

Copyright information

© Japan Human Cell Society and Springer Japan KK, part of Springer Nature 2018

Authors and Affiliations

  • Shanshan Lin
    • 1
  • Bo Zhu
    • 2
  • Guozhi Huang
    • 3
  • Qing Zeng
    • 3
  • Chuhuai Wang
    • 1
    Email author
  1. 1.Department of Rehabilitation Medicine, The First Affiliated HospitalSun Yat-sen UniversityGuangzhouChina
  2. 2.Department of Liver Surgery, Liver Transplantation CenterWest China Hospital of Sichuan UniversityChengduChina
  3. 3.Department of Rehabilitation Medicine, Zhujiang HospitalSouthern Medical UniversityGuangzhouChina

Personalised recommendations